|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of TNBC with PI3K or mTORC1/2 inhibitors results in drug-resistant, Notch-dependent CSC.
|
30564555 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway.
|
26857281 |
2016 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overall findings suggest that Chetomin inhibited the growth of human TNBC cells by caspase-dependent apoptosis and modulation of PI3K/mTOR signalling and could be used as a novel chemotherapeutic agent for the treatment of human TNBC in future.
|
29208466 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC.
|
29924958 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the effect of a statin on TNBC cells and analyzed the association of PI3K pathways using various TNBC cells in terms of PTEN loss and AKT pathways.
|
23973711 |
2013 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
|
25296970 |
2014 |
|
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of WBP2 inhibited YAP transcription and the EGFR/PI3K/Akt signaling pathway in TNBC cells, and these effects were reversed by inhibition of miR-613.
|
30092563 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AKT3 is an oncogene of known relevance in breast cancer, and as a proof of principle we show that inhibition of phosphoinositide 3-kinase (PI3K) activity, a protein upstream of AKT3, suppressed proliferation in TNBC preneoplastic cells.
|
28160548 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the PI3K/mTOR pathway in TNBC cell lines decreased notably the expression of the AR.
|
24779793 |
2014 |
|
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using three-dimensional stromal-TNBC cells cultures, we demonstrate that CXCL12 - CXCR4 signaling significantly increases growth of TNBC cells and drug resistance through activation of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways.
|
29416611 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
We review the evidence for PI3K pathway activation in TNBC, and clinical trial data for PI3K, AKT and mammalian target of rapamycin inhibitors in TNBC.
|
31050709 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings identify KDM4B as a therapeutic vulnerability in <i>PTEN</i>-deficient TNBC that otherwise would be resistant to PI3K inhibition.
|
30266800 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
The development of drugs targeting the PI3K/AKT/mTOR pathway for the treatment of TNBC is an evolving field that should take into account the efficacies and toxicities of new agents in addition to their interactions with different cancer pathways.
|
29417298 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC).
|
31703728 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.
|
25721419 |
2015 |
|
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The addition of PI3K-mTOR inhibitors to cisplatin or paclitaxel increased the activity of chemotherapy in the TNBC and LGSOC models; whereas no added activity was observed in the LADC model.
|
29156674 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer.
|
29228721 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other subtypes with variable degrees of supporting evidence exist within the nonbasal/p53wt (wild-type p53) TNBC, including a group of TNBC with PI3K (phosphoinositide 3-kinase) pathway activation that have better overall prognosis than the basal TNBC.
|
24298072 |
2014 |
|
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
|
27563827 |
2016 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanistically, DCC-2036 targeted AXL/MET, especially AXL, and regulated the downstream PI3K/Akt-NFκB signaling to exert its antitumor effect in TNBC.
|
30289981 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
As EGFR/PI3K/Akt pathway proteins are frequently altered in TNBC, we have studied the gene expression of key proteins of this pathway.
|
28766167 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Metaplastic breast cancers (MpBCs) are typically TNBCs and commonly have alterations in the PI3K/Akt/mTOR pathway.
|
30139837 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond.
|
31636720 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides a preclinical rationale to investigate the therapeutic potential for the combination of PI3K inhibition and eribulin in the difficult to treat TNBC.
|
31217901 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> The PI3K/AKT/mTOR pathway is an important oncogenic driver in triple-negative breast cancer (TNBC).
|
29675095 |
2018 |